Shots:

• Bayer to support the development- supply and key territory operations of CureVac´s COVID-19 vaccine candidate- CVnCoV and will contribute its expertise and established infrastructure in numerous area
• Curevac will be the MAH for the product while Bayer will support CureVac with country operations within the EU and additional markets. Additionally- Bayer has an option to MAH outside the EU
• The companies plan to combine their strengths for CureVac to be in a position to supply hundreds of millions of CVnCoV doses across the globe

 ­ Ref: Bayer | Image: GMPNews